Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pharmacogenetic study of vorinostat glucuronidation.

Pharmacogenetics and genomics - 1 Oct 2010

Kang Soonmo Peter, Ramirez Jacqueline, House Larry, Zhang Wei, Mirkov Snezana, Liu Wanqing, Haverfield Eden, Ratain Mark J

Abstract excerpt

High interindividual pharmacokinetic variability was observed in phase 1 studies of vorinostat (suberoylanilide hydroxamic acid), an oral histone deacetylase inhibitor. Thus, we hypothesized that the variability can be explained by genetic variants of the uridine 5'-diphosphate-glucuronosyltransferases (UGTs) involved in vorinostat metabolism. Baculosomes expressing human UGTs and 52 human liver microsomes were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Expression Regulation, Enzymologic
Share to Glucuronides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Glycosylation

Share to Hydroxamic Acids

Share to Microsomes, Liver

Share to Regression Analysis

Share to Vorinostat

Source

Open in PubMed Open full text

Identifiers

PMID: 20729791
DOI: 10.1097/FPC.0b013e32833e1b37
PMCID: PMC3636562

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

A pharmacogenetic study of vorinostat glucuronidation.PMID 20729791Read ↗

Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.Semantic proximity Read ↗

Pharmacogenomics and Histone Deacetylase InhibitorsSemantic proximity Read ↗

Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.Semantic proximity Read ↗

Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.Semantic proximity Read ↗

Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.Semantic proximity Read ↗

Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications.Semantic proximity Read ↗

UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.Semantic proximity Read ↗

UDP-glucuronosyltransferase 2B15 (UGT2B15) is the major enzyme responsible for sipoglitazar glucuronidation in humans: retrospective identification of the UGT isoform by in vitro analysis and the effect of UGT2B15*2 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.